bellerophon therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
Company profile
Ticker
BLPH
Exchange
Website
CEO
Fabian Tenenbaum
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Bellerophon Therapeutics LLC
SEC CIK
BLPH stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
5 Mar 24
8-K
Departure of Directors or Certain Officers
4 Mar 24
DEFA14A
Additional proxy soliciting materials
12 Feb 24
DEFA14A
Additional proxy soliciting materials
12 Feb 24
8-K
Entry into a Material Definitive Agreement
30 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
22 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
10 Jan 24
DEFA14A
Additional proxy soliciting materials
3 Jan 24
25-NSE
Exchange delisting
27 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
12 Dec 23
Latest ownership filings
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G
Lepercq De Neuflize Asset Management LLC
26 Jan 24
SC 13D/A
Puissance Life Science Opportunities Fund VI
17 Oct 23
SC 13D/A
Puissance Life Science Opportunities Fund VI
16 Oct 23
4
Theodore T Wang
16 Oct 23
4
Naseem Amin
9 Jun 23
4
Peter Fernandes
9 Jun 23
4
Parag Suresh Shah
9 Jun 23
4
Martin Dekker
9 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.38 mm | 4.38 mm | 4.38 mm | 4.38 mm | 4.38 mm | 4.38 mm |
Cash burn (monthly) | 2.06 mm | 577.92 k | 723.33 k | 914.08 k | 2.11 mm | 1.03 mm |
Cash used (since last report) | 12.27 mm | 3.43 mm | 4.30 mm | 5.43 mm | 12.55 mm | 6.11 mm |
Cash remaining | -7.89 mm | 947.08 k | 82.78 k | -1.05 mm | -8.16 mm | -1.73 mm |
Runway (months of cash) | -3.8 | 1.6 | 0.1 | -1.1 | -3.9 | -1.7 |
Institutional ownership, Q2 2023
26.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 24 |
Opened positions | 10 |
Closed positions | 7 |
Increased positions | 6 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 580.09 mm |
Total shares | 3.26 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tang Capital Partners | 1.06 mm | $5.31 mm |
New Mountain Investments II | 1.01 mm | $6.73 mm |
Acadian Asset Management | 265.25 k | $182.00 k |
WFC Wells Fargo & Co. | 200.08 k | $138.05 mm |
Vanguard | 145.81 k | $100.61 mm |
BLK Blackrock | 129.88 k | $89.62 mm |
Two Sigma Investments | 103.79 k | $71.61 mm |
Geode Capital Management | 95.66 k | $66.00 mm |
Renaissance Technologies | 77.30 k | $53.00 k |
NTRS Northern Trust | 38.22 k | $26.37 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Oct 23 | Puissance Capital Management | Common Stock | Sell | Dispose S | No | No | 0.1038 | 1,076,841 | 111.78 k | 0 |
7 Jun 23 | Puissance Life Science Opportunities Fund VI | Common Stock | Sell | Dispose S | No | No | 0.83 | 134,421 | 111.57 k | 1,076,841 |
7 Jun 23 | Cloyd Mary Ann | Stock Options Common Stock | Grant | Dispose A | No | No | 0.8264 | 14,607 | 12.07 k | 14,607 |
7 Jun 23 | Crispin Teufel | Stock Options Common Stock | Grant | Dispose A | No | No | 0.8264 | 14,607 | 12.07 k | 14,607 |
7 Jun 23 | Scott P Bruder | Stock Options Common Stock | Grant | Dispose A | No | No | 0.8264 | 14,607 | 12.07 k | 14,607 |